Erdafitinib

Description

Erdafitinib · CAS 1346242-81-6 · C25H30N6O2. UNII 890E37NHMV. Solubility: <1 mg/mL.

Identification

Computed Descriptors

Physical & Chemical Properties

GHS Hazard Classification

Documented Uses

• Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. The selection of patients for the treatment of locally advanced or metastatic
• Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor (FGF) receptors 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors
• Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of erdafitinib.
• Exercise caution with St. John's Wort. This herb induces the CYP3A metabolism of erdafitinib and may reduce its serum concentration.
• Take with or without food. No clinically meaningful differences with erdafitinib pharmacokinetics were observed following administration of a high-fat and high-calorie meal (800 calories to 1,000 calories with approximately 50% of total caloric content of the meal from fat) in healthy subjects.

Synonyms

Erdafitinib; 1346242-81-6; Balversa; 890E37NHMV; DTXSID001027936; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine; erdafitinibum; N'-(3,5-dimethoxyphenyl)-N'-(3-(1-methylpyrazol-4-yl)quinoxalin-6-yl)-N-propan-2-ylethane-1,2-diamine; RefChem:57639; DTXCID201513503; JNJ-42756493; N1-(3,5-dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine; MFCD28502040; Balversa (TN); ERDAFITINIB [WHO-DD]; JNJ 42756493

Frequently Asked Questions

What are the CAS number and molecular formula of Erdafitinib?

CAS 1346242-81-6; molecular formula C25H30N6O2; molecular weight — g/mol.

What other names is Erdafitinib known by?

Erdafitinib, 1346242-81-6, Balversa, 890E37NHMV, DTXSID001027936, N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine.

Is Erdafitinib classified as hazardous?

Hazard statements reported: H302, H317, H318, H335, H361.

What are the key physical properties of Erdafitinib?

Solubility: <1 mg/mL.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.